… Our findings demonstrate that erlotinib is an effective neoadjuvant regimen in patients with
EGFR-mutant locally advanced NSCLC, paving the way for its extended use in neoadjuvant …

… and safety of neoadjuvant and adjuvant targeted therapy with erlotinib compared with standard
… OS of neoadjuvant erlotinib was 42.2 months, which is a promising result for patients with …

… analysis (one patient withdrew before treatment). The ORR for neoadjuvant erlotinib versus
GC … Three (9.7%) of 31 patients and zero of 23 patients in the erlotinib and GC chemotherapy …

… maintenance erlotinib or observation, while patients with … the pT0 rate after neoadjuvant
erlotinib. Secondary endpoints … and tolerability of neoadjuvant erlotinib in patients with UC, and …

… monotherapy in early stage NSCLC patients. The purpose of this study was to investigate
erlotinib plasma and lung tumor tissue concentrations after neoadjuvant erlotinib therapy. …

… that neoadjuvant erlotinib improved the likelihood of surgery and was associated with a
good resection rate as shown by the high rate of prospective downstaging in patients with stage …

… Currently, a Dutch multicenter phase II study of neoadjuvant erlotinib in operable patients
with … to neoadjuvant erlotinib early in the course of erlotinib therapy in patients with NSCLC. …

… Conclusion: Erlotinib as neoadjuvant/adjuvant therapy for resected N2 NSCLC was
feasibility and had a promising OS. The PFS survival advantage of E did not translate to OS …

… According to predefined criteria, neoadjuvant erlotinib has low toxicity and sufficient activity
… efficacy of a short course of preoperative erlotinib in patients with early-stage NSCLC who …

… In conclusion, the use of neoadjuvant erlotinib was well tolerated in patients with nonmetastatic
HNSCC. Further study is necessary to determine whether the encouraging antitumor …